Christopher Ryan Sullivan
Chief Financial Officer · Avalo Therapeutics, Inc.
- 2026
- Sep 18, 2026
- 11
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Christopher Ryan Sullivan files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Mittie Doyle - $2.98M in AVTX purchases and sales in the last 12 months
- Paul Varki - $1.51M in AVTX purchases and sales in the last 12 months
- Jonathan Goldman - $163K in AVTX purchases and sales in the last 12 months
- Mitchell Chan - $72K in AVTX purchases and sales in the last 12 months
- Jennifer Riley - $52K in AVTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher Ryan Sullivan?
Christopher Ryan Sullivan is a corporate insider, tracked as Chief Financial Officer of Avalo Therapeutics, Inc. (AVTX). InsiderAlpha holds 11 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Christopher Ryan Sullivan submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Christopher Ryan Sullivan been buying or selling stock?
Recorded transactions: 0 open-market purchases and 17 open-market sales ($3.72M) across all tracked filings.
